ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Acquired by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC grew its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 190.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 43,341 shares of the biopharmaceutical company’s stock after acquiring an additional 28,395 shares during the period. Commonwealth Equity Services LLC’s holdings in ACADIA Pharmaceuticals were worth $795,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. KBC Group NV raised its position in shares of ACADIA Pharmaceuticals by 67.0% in the fourth quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock worth $93,000 after acquiring an additional 2,044 shares during the period. R Squared Ltd purchased a new position in shares of ACADIA Pharmaceuticals in the 4th quarter valued at about $47,000. Swiss National Bank raised its holdings in ACADIA Pharmaceuticals by 1.4% in the 4th quarter. Swiss National Bank now owns 212,104 shares of the biopharmaceutical company’s stock worth $3,892,000 after purchasing an additional 2,900 shares during the period. Diversified Trust Co boosted its position in ACADIA Pharmaceuticals by 9.8% during the fourth quarter. Diversified Trust Co now owns 35,774 shares of the biopharmaceutical company’s stock worth $656,000 after purchasing an additional 3,187 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in ACADIA Pharmaceuticals by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 35,281 shares of the biopharmaceutical company’s stock valued at $647,000 after purchasing an additional 3,378 shares during the period. Institutional investors and hedge funds own 96.71% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. StockNews.com raised ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 8th. Needham & Company LLC restated a “buy” rating and set a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They issued a “hold” rating and a $22.00 target price on the stock. Morgan Stanley restated an “equal weight” rating and set a $20.00 price target on shares of ACADIA Pharmaceuticals in a research report on Friday, March 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $27.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Eight analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, ACADIA Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $23.93.

Insiders Place Their Bets

In other ACADIA Pharmaceuticals news, EVP Mark C. Schneyer sold 3,171 shares of the firm’s stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $17.05, for a total transaction of $54,065.55. Following the completion of the sale, the executive vice president now owns 56,889 shares of the company’s stock, valued at $969,957.45. This trade represents a 5.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Elizabeth A. Garofalo sold 4,919 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total value of $89,673.37. Following the completion of the transaction, the director now directly owns 17,595 shares in the company, valued at approximately $320,756.85. This trade represents a 21.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,433 shares of company stock valued at $187,319 over the last ninety days. Company insiders own 28.30% of the company’s stock.

ACADIA Pharmaceuticals Stock Up 1.8 %

NASDAQ ACAD opened at $16.62 on Thursday. The business’s fifty day simple moving average is $18.26 and its 200-day simple moving average is $17.05. The firm has a market cap of $2.77 billion, a PE ratio of 21.31 and a beta of 0.54. ACADIA Pharmaceuticals Inc. has a 52 week low of $14.15 and a 52 week high of $20.68.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.